Business Wire

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease ...
Electropages

New RT high-reliability communication interface solution for space applications

ATA6571RT CAN FD Transceiver, a high-reliability communication solution developed specifically for space applications. This advanced transceiver supports flexible data rates up to 5Mbps, making it ...

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer ...

ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a ...
Medscape

ctDNA Testing Shows Promise in Guiding CRC Treatment Decisions

New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...
Microwaves & RF

Rad-Tolerant, High-Rel Comm Interface Bound for Space

Microchip’s ATA6571RT CAN FD transceiver supports data rates up to 5 Mb/s for a radiation-tolerant, high-reliability ...